ong-term maintenance of anti-tumor immune responses by vaccination with tri-WT1 peptide cancer vaccine WT1 Trio
Not Applicable
Recruiting
- Conditions
- Thymic cancer Thymoma Soft tissue sarcoma Malignant glioma Salivary gland cancer Head and neck mucoepidermoid carcinoma Olfactory neuroblastoma Head and neck mucosal malignant melanoma Ophthalmic malignant melanoma Cancer of the external auditory canal Testicular cancer Cancer of penis Adrenal cancer Malignant mesothelioma Cancer of the small intestine Merkel cell carcinoma Cutaneous lymphoma (Rare cancers listed above)
- Registration Number
- JPRN-UMIN000023578
- Lead Sponsor
- Osaka University Graduate School of Medicine Dept. Cancer Immunotherapy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1 A patient with active infectious disease. 2 A patient who experienced SAE (grade >=4) in the previous clinical trial of WT1 peptide vaccine 3 A patient with severe complication or complications. 4 A patient with severe mental disorder. 5 A patient who participates in any other clinical trial 6 A patient who should not be recruited to the clinical trial as determined by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method